Einsatz multimodaler Therapiekonzepte im frühen Stadium des follikulären Lymphoms

Schlüsselwörter

follikuläres Lymphom - multimodale Therapie - Radiotherapie - Immun-Chemotherapie - Radioimmuntherapie - Rituximab

Keywords

follicular lymphoma - multimodal treatment - radiotherapy - immuno-chemotherapy - radioimmunotherapy - rituximab

Literatur

• 1 Advani R, Rosenberg S A, Horning S J. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy.  J Clin Oncol. 2004;  22 1454-1459
• 2 Brugger W, Hirsch J, Grunebach F. et al . Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.  Ann Oncol. 2004;  15 1691-1698
• 3 Byrd J C, Kitada S, Flinn I W. et al . The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.  Blood. 2002;  99 1038-1043
• 4 Engelhard M, Stuschke M, Hansmann M. et al . Follicular lymphoma, immunocytoma, and mantle cell lymphoma: randomised evaluation of curative radiotherapy in limited stage nodal disease.  Ann Oncol. 2005;  16 108
• 5 Forstpointner R, Unterhalt M, Dreyling M. et al . Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).  Blood. 2006;  108 4003-4008
• 6 Golay J. et al . Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab.  Br J Haematol. 2002;  119 1314-1319
• 7 Golay J, Lazzari M, Facchinetti V. et al . CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.  Blood. 2001;  98 3383-3389
• 8 Golay J, Zaffaroni L, Vaccari T. et al . Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.  Blood. 2000;  95 3900-3908
• 9 Gospodarowicz M K, Bush R S, Brown T C, Chua T. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience.  International journal of radiation oncology, biology, physics. 1984;  10 489-497
• 10 Hirt C, Schuler F, Kiefer T. et al . Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients.  Br J Haematol. 2008;  141 631-640
• 11 Kaminski M S, Tuck M, Estes J. et al . 131I-tositumomab therapy as initial treatment for follicular lymphoma.  The New England journal of medicine. 2005;  352 441-449
• 12 Mac Manus M P, Hoppe R T. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University.  J Clin Oncol. 1996;  14 1282-1290
• 13 McLaughlin P, Fuller L, Redman J. et al . Stage I-II low-grade lymphomas: a prospective trial of combination chemotherapy and radiotherapy.  Ann Oncol. 1991;  2 Suppl 2 137-140
• 14 Neumann H, Blanck H, Koch R. et al . [Follicle centre lymphoma: treatment results for stage I and II].  Strahlenther Onkol. 2003;  179 840-846
• 15 Pedersen I M, Buhl A M, Klausen P, Geisler C H, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism.  Blood. 2002;  99 1314-1319
• 16 Seymour J F, Pro B, Fuller L M. et al . Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin’s lymphoma.  J Clin Oncol. 2003;  21 2115-2122
• 17 Skvortsova I, Popper B A, Skvortsov S. et al . Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin’s lymphoma cells.  J Radiat Res (Tokyo). 2005;  46 241-248
• 18 Soubeyran P, Eghbali H, Bonichon F. et al . Localized follicular lymphomas: prognosis and survival of stages I and II in a retrospective series of 103 patients.  Radiother Oncol. 1988;  13 91-98
• 19 Stuschke M, Hoederath A, Sack H. et al . Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a prospective multicenter study. Study Group NHL-fruhe Stadien.  Cancer. 1997;  80 2273-2284
• 20 Vaughan Hudson B, Vaughan Hudson G, MacLennan K A, Anderson L, Linch D C. Clinical stage 1 non-Hodgkin’s lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy.  Brit J Cancer. 1994;  69 1088-1093
• 21 Voss N JS, Klasa R J, al. The treatment of early stage, low grade non-Hodgkin’s lymphoma with involved field irradiation. The BCCA experience.  Ann Hematol. 2001;  80 Suppl III B153